Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-679 / ECHO-302 in first-line advanced or metastatic renal cell carcinoma
2017-002259-26Phase 3Unknown
- Sponsor
- Incyte
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Pembrolizumab plus epacadostat with Standard of care (2 arms). Primary endpoint: Progression-Free Survival. Status: unknown.
02
Drugs
pembrolizumabepacadostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2017-002259-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002259-26.